Immune response seen in Spark hemo B study

In updated interim results from an ongoing Phase I/II study to treat hemophilia B, Spark Therapeutics Inc. (NASDAQ:ONCE) and partner Pfizer Inc. (NYSE:PFE) said a single administration of the gene therapy

Read the full 313 word article

User Sign In